[1] [1] SUNG H, FERLAY J, SIEGEL R L,et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021, 71(3): 209-249. DOI:10.3322/caac.21660.

[2] [2] JIA X Y, LI Z T, ZHOU R Y,et al. Single cell and bulk RNA sequencing identifies tumor microenvironment subtypes and chemoresistance-related IGF1+ cancer-associated fibroblast in gastric cancer[J/OL]. Biochim Biophys Acta Mol Basis Dis, 2024,1870(4): 167123[2024-09-02]. https://pubmed.ncbi.nlm.nih.gov/38484940/. DOI:10.1016/j.bbadis.2024.167123.

[3] [3] XIE M L, LIANG L, YU L Y,et al. The integration of bulk and single-cell sequencing data revealed the function of FKBP10 in the gastric cancer microenvironment[J]. Transl Cancer Res, 2024, 13(2): 975-988. DOI:10.21037/tcr-23-1484.

[4] [4] POUS A, NOTARIO L, HIERRO C,et al. HER2-positive gastric cancer: the role of immunotherapy and novel therapeutic strategies[J/OL]. Int J Mol Sci, 2023, 24(14): 11403[2024-09-02]. https://pmc.ncbi.nlm.nih.gov/articles/PMC10380453/. DOI:10.3390/ijms 241411403.

[6] [6] ZHONG G C, ZHANG X M, GUO Z,et al. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CART cell therapy: a case report[J/OL]. Front Immunol, 2024, 15:1325860[2024-09-02]. https://pubmed.ncbi.nlm.nih.gov/38487523/. DOI:10.3389/fimmu.2024.1325860.

[7] [7] KUBOTA Y, SHITARA K. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer[J/OL]. Ther Adv Med Oncol, 2024, 16: 17588359231217967[2024-09-02]. https://pubmed.ncbi.nlm.nih.gov/38188462/. DOI:10.1177/17588359231217967.

[8] [8] QIAO H, WANG Y F, ZHU B D,et al. Enolase1 overexpression regulates the growth of gastric cancer cells and predicts poor survival[J]. J Cell Biochem, 2019, 120(11): 18714-18723. DOI:10.1002/jcb.29179.

[9] [9] QIAO H, WANG Y F, YUAN W Z,et al. Silencing of ENO1 by shRNA inhibits the proliferation of gastric cancer cells[J/OL]. Technol Cancer Res Treat, 2018, 17: 1533033818784411[2024-09-02]. https://pubmed.ncbi.nlm.nih.gov/29986635/. DOI:10.1177/1533033818784411.

[10] [10] ZHOU X, YAO K, ZHANG L,et al. Identification of differentiation-related proteins in gastric adenocarcinoma tissues by proteomics[J]. Technol Cancer Res Treat, 2016, 15(5): 697-706. DOI:10.1177/1533034615595792.

[11] [11] HUPPERTZ I, PEREZ-PERRI J I, MANTAS P,et al. Riboregulation of Enolase 1 activity controls glycolysis and embryonic stem cell differentiation[J]. Mol Cell, 2022, 82(14): 2666-2680. DOI:10.1016/j.molcel.2022.05.019

[12] [12] GAUDET P, LOGIE C, LOVERING R C,et al. Gene Ontology representation for transcription factor functions[J/OL]. Biochim Biophys Acta Gene Regul Mech, 2021, 1864(11/12): 194752[2024-09-02]. https://pubmed.ncbi.nlm.nih.gov/34461313/. DOI:10.1016/j.bbagrm.2021.194752.

[13] [13] GAUDET P, DESSIMOZ C. Gene ontology: pitfalls, biases, and remedies[J]. Methods Mol Biol, 2017, 1446: 189-205. DOI:10.1007/978-1-4939-3743-1_14.

[14] [14] KANEHISA M, FURUMICHI M, SATO Y,et al. KEGG for taxonomy-based analysis of pathways and genomes[J]. Nucleic Acids Res, 2023, 51(D1): D587-D592. DOI:10.1093/nar/gkac963.

[15] [15] KANEHISA M, SATO Y, KAWASHIMA M,et al. KEGG as a reference resource for gene and protein annotation[J]. Nucleic Acids Res, 2016, 44(D1): D457-D462. DOI:10.1093/nar/gkv1070.

[16] [16] WU J M, MAO X Z, CAI T,et al. KOBAS server: a web-based platform for automated annotation and pathway identification[J]. Nucleic Acids Res, 2006, 34(Web Server issue): W720-W724. DOI:10.1093/nar/gkl167.

[17] [17] ADAMS W T, SKOPEK T R. Statistical test for the comparison of samples from mutational spectra[J]. J Mol Biol, 1987, 194(3): 391-396. DOI:10.1016/0022-2836(87)90669-3.

[18] [18] GLICKMAN M E, RAO S R, SCHULTZ M R. False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies[J]. J Clin Epidemiol, 2014, 67(8): 850-857. DOI:10.1016/j.jclinepi.2014.03.012.

[19] [19] GU J R, ZHONG K Q, WANG L G,et al. ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cellsviaEMT pathway[J/OL]. Front Oncol, 2022, 12: 1013035[2024-09-02]. https://pubmed.ncbi.nlm.nih.gov/36620599/. DOI:10.3389/fonc.2022.1013035.

[20] [20] HONG M Q, LI T T, XUE W H,et al. Genetic engineering of baculovirus-insect cell system to improve protein production[J/OL]. Front Bioeng Biotechnol, 2022, 10: 994743[2024-09-02]. https://pubmed.ncbi.nlm.nih.gov/36204465/. DOI:10.3389/fbioe.2022.994743.

[21] [21] DINH D T D, KUHL S, GRTZ L,et al. Expression of ENO1 is up-regulated in low-grade glioma and positively correlated with meningioma grade[J]. Anticancer Res, 2022, 42(5): 2319-2326. DOI:10.21873/anticanres.15711.

[22] [22] ZHANG T, SUN L C, HAO Y J,et al. ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1[J]. Nat Cancer, 2022, 3(1): 75-89. DOI:10.1038/s43018-021-00299-1.

[23] [23] CASTELLO A, HENTZE M W, PREISS T. Metabolic enzymes enjoying new partnerships as RNA-binding proteins[J]. Trends Endocrinol Metab, 2015, 26(12): 746-757. DOI:10.1016/j.tem.2015.09.012.

[25] [25] SUN Q, CHEN X X, MA J H,et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth[J]. Proc Natl Acad Sci USA, 2011, 108(10): 4129-4134. DOI:10.1073/pnas.1014769108.

[26] [26] ZHAN P P, ZHAO S H, YAN H,et al. -enolase promotes tumorigenesis and metastasisviaregulating AMPK/mTOR pathway in colorectal cancer[J]. Mol Carcinog, 2017, 56(5): 1427-1437. DOI:10.1002/mc.22603.

[27] [27] SHI Y Q, LIU J, ZHANG R Y,et al. Targeting endothelial ENO1 (alpha-enolase)-PI3K-Akt-mTOR axis alleviates hypoxic pulmonary hypertension[J]. Hypertension, 2023, 80(5): 1035-1047. DOI:10.1161/HYPERTENSIONAHA.122.19857.

[28] [28] SONG Y, LUO Q, LONG H,et al. Correction: Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma[J/OL]. Mol Cancer, 2015, 13: 235[2024-09-02]. https://pubmed.ncbi.nlm.nih.gov/25600072/. DOI:10.1186/1476-4598-13-235.

[30] [30] OHTSU A, AJANI J A, BAI Y X,et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase Ⅲ GRANITE-1 study[J]. J Clin Oncol, 2013, 31(31):3935-3943. DOI:10.1200/JCO.2012.48.3552.

[31] [31] WANG C, JIANG J L, JI J,et al. PKM2 promotes cell migration and inhibits autophagy by mediating PI3K/AKT activation and contributes to the malignant development of gastric cancer[J/OL]. Sci Rep, 2017, 7(1): 2886[2024-09-02]. https://pubmed.ncbi.nlm.nih.gov/28588255/. DOI:10.1038/s41598-017-03031-1.